 [
    {
        "id": 5398,
        "drug_name": "ADAKVEO (crizanlizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-15",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/72d8bac9-2ce7-44de-ba9e-578e5a11b8e2",
        "note": "FDA Approval announced November 15, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6232,
        "drug_name": "ABRILADA (adalimumab-afzb)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Bosimilar to Humira (adalimumab)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-18",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions",
        "note": "FDA Approval announced November 18, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3069,
        "drug_name": "GIVLAARI (givosiran)",
        "clinical_trial_id": "NCT03338816",
        "has_trial_insight_page": 0,
        "indication": "Acute hepatic porphyrias",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-20",
        "link": "http:\/\/investors.alnylam.com\/news-releases\/news-release-details\/alnylam-announces-approval-givlaaritm-givosiran-us-food-and-drug",
        "note": "FDA approval announced November 20, 2019.",
        "company_entity_id": 32,
        "company_ticker": "ALNY",
        "company_name": "Alnylam Pharmaceuticals Inc.",
        "company_price": "146.6500",
        "company_change": -2.45,
        "company_percent_change": -1.6400000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 125945793,
        "price_change_sparkline": [
            [
                172.91,
                1706677200
            ],
            [
                174.92,
                1706763600
            ],
            [
                173.06,
                1706850000
            ],
            [
                170.7,
                1707109200
            ],
            [
                172.18,
                1707195600
            ],
            [
                168.6,
                1707282000
            ],
            [
                169.5,
                1707368400
            ],
            [
                170.03,
                1707454800
            ],
            [
                169.34,
                1707714000
            ],
            [
                162,
                1707800400
            ],
            [
                164.15,
                1707886800
            ],
            [
                147.43,
                1707973200
            ],
            [
                147,
                1708059600
            ],
            [
                149.69,
                1708405200
            ],
            [
                154.74,
                1708491600
            ],
            [
                162.81,
                1708578000
            ],
            [
                157.65,
                1708664400
            ],
            [
                158.66,
                1708923600
            ],
            [
                159,
                1709010000
            ],
            [
                155.23,
                1709096400
            ],
            [
                151.09,
                1709182800
            ],
            [
                152.61,
                1709269200
            ],
            [
                150.04,
                1709528400
            ],
            [
                149.68,
                1709614800
            ],
            [
                149.66,
                1709701200
            ],
            [
                149.86,
                1709787600
            ],
            [
                149.82,
                1709874000
            ],
            [
                149.1,
                1710129600
            ],
            [
                146.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4844,
        "drug_name": "CALQUENCE (acalabrutinib)",
        "clinical_trial_id": "NCT02970318",
        "has_trial_insight_page": 1,
        "indication": "Chronic lymphocytic leukaemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-21",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html",
        "note": "FDA Approval announced November 21, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5079,
        "drug_name": "Exservan (riluzole) Oral Film",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Amyotrophic Lateral Sclerosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-23",
        "link": "https:\/\/investors.aquestive.com\/news-releases\/news-release-details\/aquestive-therapeutics-receives-fda-approval-exservantm-riluzole",
        "note": "FDA Approval announced November 22, 2019.",
        "company_entity_id": 582,
        "company_ticker": "AQST",
        "company_name": "Aquestive Therapeutics Inc.",
        "company_price": "5.1000",
        "company_change": 0.16,
        "company_percent_change": 3.24,
        "company_optionable": 1,
        "company_number_of_shares": 73301201,
        "price_change_sparkline": [
            [
                2.39,
                1706677200
            ],
            [
                2.67,
                1706763600
            ],
            [
                2.63,
                1706850000
            ],
            [
                2.7,
                1707109200
            ],
            [
                2.79,
                1707195600
            ],
            [
                2.64,
                1707282000
            ],
            [
                2.68,
                1707368400
            ],
            [
                2.75,
                1707454800
            ],
            [
                2.77,
                1707714000
            ],
            [
                2.65,
                1707800400
            ],
            [
                2.68,
                1707886800
            ],
            [
                2.72,
                1707973200
            ],
            [
                2.695,
                1708059600
            ],
            [
                2.65,
                1708405200
            ],
            [
                2.51,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.57,
                1708664400
            ],
            [
                2.85,
                1708923600
            ],
            [
                3.2,
                1709010000
            ],
            [
                3.65,
                1709096400
            ],
            [
                3.67,
                1709182800
            ],
            [
                4.24,
                1709269200
            ],
            [
                4.18,
                1709528400
            ],
            [
                4.19,
                1709614800
            ],
            [
                5.03,
                1709701200
            ],
            [
                5.68,
                1709787600
            ],
            [
                4.88,
                1709874000
            ],
            [
                4.94,
                1710129600
            ],
            [
                5.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3137,
        "drug_name": "OXBRYTA (voxelotor)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-11-25",
        "link": "https:\/\/ir.gbt.com\/news-releases\/news-release-details\/fda-approves-oxbrytatm-voxelotor-first-medicine-specifically",
        "note": "FDA Approval announced November 25, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4646,
        "drug_name": "TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Squamous non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-03",
        "link": "https:\/\/www.roche.com\/investors\/updates\/inv-update-2019-12-04.htm",
        "note": "FDA Approval announced December 3, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2997,
        "drug_name": "ABP 710",
        "clinical_trial_id": "NCT02937701",
        "has_trial_insight_page": 0,
        "indication": "REMICADE biosimilar -  rheumatoid arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-06",
        "link": "http:\/\/investors.amgen.com\/news-releases\/news-release-details\/fda-approves-amgens-avsolatm-infliximab-axxq-same-indications",
        "note": "FDA Approval announced December 6, 2019.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2394,
        "drug_name": "Golodirsen - Exon 53",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Duchenne muscular dystrophy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-12",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-grants-accelerated-approval-to-first-targeted-treatment-for-rare-duchenne-muscular-dystrophy-mutation-300974396.html",
        "note": "FDA Approval announced December 12, 2019.",
        "company_entity_id": 285,
        "company_ticker": "SRPT",
        "company_name": "Sarepta Therapeutics Inc.",
        "company_price": "122.0000",
        "company_change": 0.42,
        "company_percent_change": 0.35,
        "company_optionable": 1,
        "company_number_of_shares": 93855410,
        "price_change_sparkline": [
            [
                118.99,
                1706677200
            ],
            [
                122.83,
                1706763600
            ],
            [
                121.27,
                1706850000
            ],
            [
                125.55,
                1707109200
            ],
            [
                126.41,
                1707195600
            ],
            [
                126.05,
                1707282000
            ],
            [
                127.38,
                1707368400
            ],
            [
                126.87,
                1707454800
            ],
            [
                127.32,
                1707714000
            ],
            [
                124.19,
                1707800400
            ],
            [
                124.3,
                1707886800
            ],
            [
                124.89,
                1707973200
            ],
            [
                134.61,
                1708059600
            ],
            [
                136.14,
                1708405200
            ],
            [
                132.29,
                1708491600
            ],
            [
                134.78,
                1708578000
            ],
            [
                136.53,
                1708664400
            ],
            [
                137.65,
                1708923600
            ],
            [
                141.53,
                1709010000
            ],
            [
                137.5,
                1709096400
            ],
            [
                127.9,
                1709182800
            ],
            [
                128.67,
                1709269200
            ],
            [
                123.88,
                1709528400
            ],
            [
                122.85,
                1709614800
            ],
            [
                120.31,
                1709701200
            ],
            [
                120.78,
                1709787600
            ],
            [
                124.37,
                1709874000
            ],
            [
                121.58,
                1710129600
            ],
            [
                122,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5835,
        "drug_name": "NOURESS (AV001)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Neonate Patients Requiring Total Parental Nutrition (TPN)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-16",
        "link": "http:\/\/investors.avadel.com\/news-releases\/news-release-details\/avadel-pharmaceuticals-receives-us-fda-approval-nouresstm-av001",
        "note": "FDA Approval announced December 16, 2019.",
        "company_entity_id": 365,
        "company_ticker": "AVDL",
        "company_name": "Avadel Pharmaceuticals plc",
        "company_price": "15.9700",
        "company_change": -0.030000000000000027,
        "company_percent_change": -0.18999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 90576998,
        "price_change_sparkline": [
            [
                14.39,
                1706677200
            ],
            [
                14.72,
                1706763600
            ],
            [
                14.69,
                1706850000
            ],
            [
                14.55,
                1707109200
            ],
            [
                15.4,
                1707195600
            ],
            [
                14.71,
                1707282000
            ],
            [
                14.7,
                1707368400
            ],
            [
                14.42,
                1707454800
            ],
            [
                14.65,
                1707714000
            ],
            [
                14.15,
                1707800400
            ],
            [
                14.25,
                1707886800
            ],
            [
                14.2,
                1707973200
            ],
            [
                13.57,
                1708059600
            ],
            [
                12.86,
                1708405200
            ],
            [
                12.68,
                1708491600
            ],
            [
                12.6,
                1708578000
            ],
            [
                12.62,
                1708664400
            ],
            [
                12.99,
                1708923600
            ],
            [
                13.31,
                1709010000
            ],
            [
                12.55,
                1709096400
            ],
            [
                12.78,
                1709182800
            ],
            [
                13.72,
                1709269200
            ],
            [
                16.13,
                1709528400
            ],
            [
                15.81,
                1709614800
            ],
            [
                16.32,
                1709701200
            ],
            [
                16.035,
                1709787600
            ],
            [
                16.35,
                1709874000
            ],
            [
                16,
                1710129600
            ],
            [
                15.97,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2452,
        "drug_name": "PADCEV (enfortumab vedotin)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Urothelial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-18",
        "link": "http:\/\/bit.ly\/2M49UQ7",
        "note": "FDA Approval announced December 18, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2781,
        "drug_name": "ARAZLO (tazarotene)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acne",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-19",
        "link": "https:\/\/ir.bauschhealth.com\/tools\/viewpdf.aspx?page={24248C63-EEC6-4176-82D8-60DD13C07D50}",
        "note": "FDA Approval announced December 19, 2019.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3600,
        "drug_name": "CAPLYTA  (Lumateperone)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Schizophrenia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-23",
        "link": "https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/fda-approves-intra-cellular-therapies-novel-antipsychotic",
        "note": "FDA Approval announced December 23, 2019.",
        "company_entity_id": 176,
        "company_ticker": "ITCI",
        "company_name": "Intra-Cellular Therapies Inc.",
        "company_price": "64.3700",
        "company_change": -1.06,
        "company_percent_change": -1.62,
        "company_optionable": 1,
        "company_number_of_shares": 96807191,
        "price_change_sparkline": [
            [
                67.34,
                1706677200
            ],
            [
                68.19,
                1706763600
            ],
            [
                67.25,
                1706850000
            ],
            [
                69,
                1707109200
            ],
            [
                70.09,
                1707195600
            ],
            [
                68.57,
                1707282000
            ],
            [
                71.6,
                1707368400
            ],
            [
                72.77,
                1707454800
            ],
            [
                72.73,
                1707714000
            ],
            [
                70.4,
                1707800400
            ],
            [
                71.99,
                1707886800
            ],
            [
                74.89,
                1707973200
            ],
            [
                75.65,
                1708059600
            ],
            [
                73.7,
                1708405200
            ],
            [
                73.28,
                1708491600
            ],
            [
                71.93,
                1708578000
            ],
            [
                70.16,
                1708664400
            ],
            [
                71.56,
                1708923600
            ],
            [
                72.9,
                1709010000
            ],
            [
                71.13,
                1709096400
            ],
            [
                69.52,
                1709182800
            ],
            [
                71.49,
                1709269200
            ],
            [
                67.23,
                1709528400
            ],
            [
                66.62,
                1709614800
            ],
            [
                66.03,
                1709701200
            ],
            [
                66.72,
                1709787600
            ],
            [
                67.48,
                1709874000
            ],
            [
                65.43,
                1710129600
            ],
            [
                64.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4495,
        "drug_name": "UBRELVY (Ubrogepant)",
        "clinical_trial_id": "NCT02867709",
        "has_trial_insight_page": 0,
        "indication": "Migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-23",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/allergan-receives-us-fda-approval-for-ubrelvy-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults-300979082.html",
        "note": "FDA Approval announced December 23, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4484,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "NCT02184195",
        "has_trial_insight_page": 0,
        "indication": "Pancreatic cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-30",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html",
        "note": "FDA Approval announced December 30, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4484,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "NCT02184195",
        "has_trial_insight_page": 0,
        "indication": "Pancreatic cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-12-30",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer-30122019.html",
        "note": "FDA Approval announced December 30, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6274,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "NMIBC Bladder cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-08",
        "link": "http:\/\/bit.ly\/2QEfKuh",
        "note": "FDA Approval announced January 8, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2056,
        "drug_name": "AYVAKIT (avapritinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-09",
        "link": "http:\/\/ir.blueprintmedicines.com\/news-releases\/news-release-details\/blueprint-medicines-announces-fda-approval-ayvakittm-avapritinib",
        "note": "FDA Approval announced January 9, 2020.",
        "company_entity_id": 439,
        "company_ticker": "BPMC",
        "company_name": "Blueprint Medicines Corporation",
        "company_price": "89.7000",
        "company_change": 0.23,
        "company_percent_change": 0.26,
        "company_optionable": 1,
        "company_number_of_shares": 61232297,
        "price_change_sparkline": [
            [
                79.53,
                1706677200
            ],
            [
                79.88,
                1706763600
            ],
            [
                79.58,
                1706850000
            ],
            [
                76.66,
                1707109200
            ],
            [
                77.17,
                1707195600
            ],
            [
                74.2,
                1707282000
            ],
            [
                74.16,
                1707368400
            ],
            [
                76.54,
                1707454800
            ],
            [
                77.54,
                1707714000
            ],
            [
                73.17,
                1707800400
            ],
            [
                76.8,
                1707886800
            ],
            [
                87.57,
                1707973200
            ],
            [
                90.26,
                1708059600
            ],
            [
                91.25,
                1708405200
            ],
            [
                87.26,
                1708491600
            ],
            [
                86,
                1708578000
            ],
            [
                89.49,
                1708664400
            ],
            [
                95.05,
                1708923600
            ],
            [
                99.79,
                1709010000
            ],
            [
                95.45,
                1709096400
            ],
            [
                93.52,
                1709182800
            ],
            [
                95.12,
                1709269200
            ],
            [
                90.8,
                1709528400
            ],
            [
                89.67,
                1709614800
            ],
            [
                90.38,
                1709701200
            ],
            [
                92.04,
                1709787600
            ],
            [
                92.3,
                1709874000
            ],
            [
                89.47,
                1710129600
            ],
            [
                89.7,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6068,
        "drug_name": "TEPEZZA (Teprotumumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Thyroid Eye Disease (TED)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200121006017\/en\/",
        "note": "FDA Approval announced January 21, 2020.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4571,
        "drug_name": "TAZVERIK (Tazemetostat)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Epithelioid Sarcoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200123005858\/en\/",
        "note": "FDA approval announced January 23, 2020.",
        "company_entity_id": 132,
        "company_ticker": "EPZM",
        "company_name": "Epizyme Inc.",
        "company_price": "1.4700",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 168364752,
        "statuses": []
    },
    {
        "id": 5851,
        "drug_name": "TRIJARDY XR (Empagliflozin, linagliptin and metformin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Type 2 Diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-27",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/us-fda-approves-only-triple-combination-tablet-jardiancer-adults",
        "note": "FDA Approval announced January 27, 2020.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6102,
        "drug_name": "DIFICID (fidaxomicin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Clostridium difficile infections (CDI)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-01-27",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20200127005296\/en\/",
        "note": "FDA Approval announced January 27, 2020.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3244,
        "drug_name": "TWIRLA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Contraceptive patch ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-14",
        "link": "https:\/\/ir.agiletherapeutics.com\/news-releases\/news-release-details\/fda-approves-agile-therapeutics-incs-twirlar-levonorgestrel-and",
        "note": "FDA Approval announced February 14, 2020.",
        "company_entity_id": 24,
        "company_ticker": "AGRX",
        "company_name": "Agile Therapeutics Inc.",
        "company_price": "0.7290",
        "company_change": 0.01,
        "company_percent_change": 1.53,
        "company_optionable": 0,
        "company_number_of_shares": 2511657,
        "price_change_sparkline": [
            [
                1.53,
                1706677200
            ],
            [
                1.51,
                1706763600
            ],
            [
                1.47,
                1706850000
            ],
            [
                1.43,
                1707109200
            ],
            [
                1.51,
                1707195600
            ],
            [
                1.28,
                1707282000
            ],
            [
                1.2,
                1707368400
            ],
            [
                1.1701,
                1707454800
            ],
            [
                1.19,
                1707714000
            ],
            [
                1.2,
                1707800400
            ],
            [
                1.2,
                1707886800
            ],
            [
                1.2224,
                1707973200
            ],
            [
                1.2,
                1708059600
            ],
            [
                1.05,
                1708405200
            ],
            [
                0.9922,
                1708491600
            ],
            [
                0.9474,
                1708578000
            ],
            [
                0.89,
                1708664400
            ],
            [
                0.8082,
                1708923600
            ],
            [
                0.7906,
                1709010000
            ],
            [
                0.7685,
                1709096400
            ],
            [
                0.795,
                1709182800
            ],
            [
                0.85,
                1709269200
            ],
            [
                0.8552,
                1709528400
            ],
            [
                0.82,
                1709614800
            ],
            [
                0.8063,
                1709701200
            ],
            [
                0.765,
                1709787600
            ],
            [
                0.745,
                1709874000
            ],
            [
                0.718,
                1710129600
            ],
            [
                0.734,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3753,
        "drug_name": "Intravenous (IV) meloxicam",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute pain following bunionectomy surgery",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2020-02-20",
        "link": "https:\/\/www.baudaxbio.com\/news-and-investors\/press-releases\/detail\/160\/baudax-bio-announces-fda-approval-of-anjeso-for-the",
        "note": "FDA Approval announced February 20, 2020.",
        "company_entity_id": 2399,
        "company_ticker": "BXRXQ",
        "company_name": "Baudax Bio Inc.",
        "company_price": "0.0155",
        "company_change": 0,
        "company_percent_change": 4.03,
        "company_optionable": 0,
        "company_number_of_shares": 43593082,
        "price_change_sparkline": [
            [
                0.0245,
                1706677200
            ],
            [
                0.02415,
                1706763600
            ],
            [
                0.024,
                1706850000
            ],
            [
                0.0222,
                1707109200
            ],
            [
                0.0221,
                1707195600
            ],
            [
                0.0245,
                1707282000
            ],
            [
                0.0256,
                1707368400
            ],
            [
                0.028,
                1707454800
            ],
            [
                0.025,
                1707714000
            ],
            [
                0.02674,
                1707800400
            ],
            [
                0.028,
                1707886800
            ],
            [
                0.0222,
                1707973200
            ],
            [
                0.0202,
                1708059600
            ],
            [
                0.0229,
                1708405200
            ],
            [
                0.022425,
                1708491600
            ],
            [
                0.021975,
                1708578000
            ],
            [
                0.0201,
                1708664400
            ],
            [
                0.0179,
                1709269200
            ],
            [
                0.018,
                1709528400
            ],
            [
                0.016,
                1709614800
            ],
            [
                0.0157,
                1709701200
            ],
            [
                0.016,
                1709787600
            ],
            [
                0.01475,
                1709874000
            ],
            [
                0.0149,
                1710129600
            ]
        ],
        "statuses": []
    }
]